INT91703

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 2000
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 78
Total Number 80
Disease Relevance 53.78
Pain Relevance 13.50

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Myoz1)
Anatomy Link Frequency
T-cell 7
skin 3
heart 3
neurons 3
outflow 1
Myoz1 (Mus musculus)
Pain Link Frequency Relevance Heat
withdrawal 157 99.96 Very High Very High Very High
Potency 26 99.92 Very High Very High Very High
Neuronal nitric oxide synthase 1 99.78 Very High Very High Very High
corticosteroid 411 99.76 Very High Very High Very High
Leflunomide 9 99.62 Very High Very High Very High
beta blocker 1 99.52 Very High Very High Very High
cytokine 201 99.32 Very High Very High Very High
antagonist 155 98.96 Very High Very High Very High
Pain 89 98.78 Very High Very High Very High
depression 60 98.76 Very High Very High Very High
Disease Link Frequency Relevance Heat
Drug Induced Neurotoxicity 7 99.92 Very High Very High Very High
Pruritus 848 99.84 Very High Very High Very High
Vasculitis 124 99.84 Very High Very High Very High
Hypertension 51 99.76 Very High Very High Very High
Skin Diseases 21 99.64 Very High Very High Very High
Cancer 115 99.46 Very High Very High Very High
Nephrotoxicity 33 99.38 Very High Very High Very High
Renal Disease 138 99.28 Very High Very High Very High
Sudden Death 24 99.24 Very High Very High Very High
Toxicity 37 99.12 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Calcineurin inhibition by CsA and tacrolimus alters sympathetic outflow, which may play a role in the mediation of neurotoxic and hypertensive adverse events.
Negative_regulation (inhibition) of Calcineurin in outflow associated with hypertension
1) Confidence 0.58 Published 2000 Journal Transpl. Int. Section Abstract Doc Link 11052266 Disease Relevance 1.52 Pain Relevance 0.15
Tacrolimus exerts its immunosuppressive effects by the inhibition of calcineurin, leading to interference with T-cell activation.
Negative_regulation (inhibition) of calcineurin in T-cell
2) Confidence 0.51 Published 2006 Journal Expert Opin Pharmacother Section Abstract Doc Link 16370926 Disease Relevance 0.71 Pain Relevance 0.29
Ibuprofen-induced Walker 256 tumor cell death: cytochrome c release from functional mitochondria and enhancement by calcineurin inhibition.
Negative_regulation (inhibition) of calcineurin associated with cancer and death
3) Confidence 0.51 Published 2004 Journal Biochem. Pharmacol. Section Title Doc Link 15498510 Disease Relevance 1.10 Pain Relevance 0.10
FK506, a calcineurin inhibitor like cyclosporin A, also increased ibuprofen-induced cell death.
Negative_regulation (inhibitor) of calcineurin associated with death
4) Confidence 0.51 Published 2004 Journal Biochem. Pharmacol. Section Abstract Doc Link 15498510 Disease Relevance 1.10 Pain Relevance 0.08
Neurotoxicity of calcineurin inhibitors: impact and clinical management.
Negative_regulation (inhibitors) of calcineurin associated with drug induced neurotoxicity
5) Confidence 0.43 Published 2000 Journal Transpl. Int. Section Title Doc Link 11052266 Disease Relevance 1.28 Pain Relevance 0.16
Incapacitating lower limb pain syndrome in cord blood stem cell transplant recipients with calcineurin inhibitor.
Negative_regulation (inhibitor) of calcineurin in stem cell associated with pain
6) Confidence 0.37 Published 2004 Journal Pathol. Oncol. Res. Section Title Doc Link 15619640 Disease Relevance 0.64 Pain Relevance 0.57
Its mechanism of action, independent of calcineurin, is different from that of ciclosporin and tacrolimus and because of its lack of nephrotoxicity, it is a good alternative for calcineurin inhibitors in patients with renal dysfunction.
Negative_regulation (inhibitors) of calcineurin associated with nephrotoxicity and renal disease
7) Confidence 0.33 Published 2010 Journal Acta Chir. Belg. Section Abstract Doc Link 20690519 Disease Relevance 0.56 Pain Relevance 0.05
CONCLUSIONS: Interventions aimed at reducing pain associated with CIPS may include the initiation of calcium-channel blocker therapy and conversion to an alternative calcineurin inhibitor.


Negative_regulation (inhibitor) of calcineurin
8) Confidence 0.30 Published 2009 Journal Ann Pharmacother Section Body Doc Link 19318596 Disease Relevance 0 Pain Relevance 0
Our case also strengthens previous observations as to the efficacy and safety of topical calcineurin inhibitors in this dermatosis.
Negative_regulation (inhibitors) of calcineurin associated with skin diseases
9) Confidence 0.30 Published 2009 Journal Dermatology (Basel) Section Abstract Doc Link 19339769 Disease Relevance 0.61 Pain Relevance 0.10
The spectrum of neurological disturbances caused by calcineurin inhibitors range from very mild symptoms as paraesthesiae, tremor, headache or flushing, to severe changes that may cause lethal outcome.
Negative_regulation (inhibitors) of calcineurin associated with tremor, headache and increased venous pressure under development
10) Confidence 0.30 Published 2008 Journal Acta Med Croatica Section Abstract Doc Link 18578336 Disease Relevance 1.32 Pain Relevance 0.16
Due to our findings, topical calcineurin inhibitors may be a safe treatment alternative.
Negative_regulation (inhibitors) of calcineurin
11) Confidence 0.22 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661653 Disease Relevance 1.59 Pain Relevance 0.45
Analysis detected a preclinical decrease of the calcium/calmodulin-dependent phosphatase calcineurin (CaN) in granule neurons, suggesting that dysregulation of CaN activity induced by mutant PrP may be responsible for the cerebellar dysfunction in Tg(PG14) mice.
Negative_regulation (decrease) of calcineurin in neurons associated with targeted disruption and cerebellar diseases
12) Confidence 0.17 Published 2006 Journal Proteomics Section Abstract Doc Link 16572473 Disease Relevance 1.28 Pain Relevance 0.14
All patients received topical calcineurin inhibitors in an open uncontrolled surveillance study.
Negative_regulation (inhibitors) of calcineurin
13) Confidence 0.17 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661653 Disease Relevance 1.04 Pain Relevance 0.56
BACKGROUND: The calcineurin inhibitor, cyclosporine, is widely used for preventing allograft rejection in organ transplantation.
Negative_regulation (inhibitor) of calcineurin associated with organ transplantation
14) Confidence 0.15 Published 2007 Journal Anesth. Analg. Section Abstract Doc Link 17959987 Disease Relevance 0.50 Pain Relevance 0.23
FK506 is an immunophilin-binding ligand that inhibits calcineurin and decreases nitric oxide (NO) production in the nervous tissues.
Negative_regulation (inhibits) of calcineurin in nervous tissues
15) Confidence 0.15 Published 2003 Journal Behav Pharmacol Section Abstract Doc Link 12658072 Disease Relevance 0.05 Pain Relevance 0.58
The development of topical calcineurin inhibitors resulted in a significant improvement in the treatment of atopic dermatitis (Simpson and Noble 2005).
Negative_regulation (inhibitors) of calcineurin associated with eczema
16) Confidence 0.14 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661653 Disease Relevance 0.58 Pain Relevance 0.19
According to the severity of prurigo nodularis, both calcineurin inhibitors achieved a significant improvement of pruritus and skin lesions consisting of papules and flat nodules.
Negative_regulation (inhibitors) of calcineurin in papules associated with pruritus
17) Confidence 0.14 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661653 Disease Relevance 1.55 Pain Relevance 0.33
Also, other types of localized and generalized pruritus of unknown origin without primary skin lesions could be influenced by topical calcineurin inhibitors.
Negative_regulation (inhibitors) of calcineurin in skin associated with pruritus
18) Confidence 0.14 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661653 Disease Relevance 1.70 Pain Relevance 0.47
In the current surveillance study, the antipruritic potency of calcineurin inhibitors in prurigo nodularis, generalized and localized pruritus including genitoanal pruritus was evaluated.
Negative_regulation (inhibitors) of calcineurin associated with pruritus and potency
19) Confidence 0.14 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661653 Disease Relevance 1.53 Pain Relevance 0.31
Treatment of pruritic diseases with topical calcineurin inhibitors

The introduction of topical calcineurin inhibitors resulted in a significant improvement in the treatment of atopic dermatitis.

Negative_regulation (inhibitors) of calcineurin associated with eczema and disease
20) Confidence 0.14 Published 2006 Journal Therapeutics and Clinical Risk Management Section Title Doc Link PMC1661653 Disease Relevance 1.14 Pain Relevance 0.16

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox